TY  - JOUR
TI  - Prognostic factors in patients undergoing pulmonary resection for sarcomatoid carcinomas of the lung
AB  - Background: Pulmonary sarcomatoid carcinomas are very rare lungneoplasms, and no consensus exists regarding their optimal treatment.The prognosis of sarcomatoid carcinomas has been reported to be unfavorable compared with non-small-cell lung cancers; however, prognostic factors in patients undergoing surgery for sarcomatoid carcinomasremain unclear.Aims: To analyze clinicopathologic prognostic factors and survivaloutcomes in patients who underwent surgery for pulmonary sarcomatoid carcinoma.Study Design: Retrospective cross-sectional study.Methods: We designed a retrospective cross-sectional study in patientswho underwent surgery for pulmonary sarcomatoid carcinomas andstatistically analyzed the prognostic factors regarding clinicopathologicfeatures with respect to survival outcomes.Results: We had a total of 44 patients with sarcomatoid carcinoma whohad pulmonary resection. Sex distribution was 34 (77%) males and 10(22.7%) females, which was determined by declaration. The mean ageof patients was 57.3 ± 16 years with a median of 60 years. The 5-yearprogression-free survival and overall survival rates were 59% and 58%,respectively. The 5-year survival rates were significantly different fortumors > 5 cm (P = 0.044), tumorstatus (T) (P=0.016), lymph node status (N) (P=0.005), and pathologic tumor-node-metastasis (TNM) stage(P = 0.0001 ). However, histologic subtype (P = 0.628) and adjuvanttreatment (P = 0.804) did not have any significant effect on survival.Similarly, the significant prognostic factors in univariate analysis weretumor size (P = 0.085), T status (P = 0.005), N status (P = 0.028), andpathologic TNM stage (P = 0.0001). Multivariate analysis showed onlyT status (P = 0.058), N status (P = 0.018), and pathologic TNM stage(P = 0.019) as independent prognostic factors, with statistical power of87%, 43.1% and 21.2%.Conclusion: Surgery appears to be an optimal treatment with favorableoutcomes for patients with pulmonary sarcomatoid carcinoma. Patientswith small tumors at earlier stages are very likely to benefit from surgery, regardless of histologic subtype.
AU  - Amirov, Fahmin
AU  - KARA, MURAT
AU  - Duman, Salih
AU  - Ozkan, Berker
AU  - Ozluk, Yasemin
AU  - Toker, Alper
AU  - Cimenoglu, Berk
AU  - Erdoğdu, Eren
AU  - YILMAZBAYHAN, EMINE DILEK
DO  - 10.4274/balkanmedj.galenos.2020.2020.7.45
PY  - 2021
JO  - Balkan Medical Journal
VL  - 38
IS  - 2
SN  - 2146-3123
SP  - 104
EP  - 110
DB  - TRDizin
UR  - http://search/yayin/detay/411556
ER  -